How to buy Turning Point Therapeutics stock - 13 April

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Turning Point Therapeutics stock

Own Turning Point Therapeutics stock in just a few minutes.

Turning Point Therapeutics, Inc is a biotechnology business based in the US. Turning Point Therapeutics shares (TPTX) are listed on the NASDAQ and all prices are listed in US Dollars. Turning Point Therapeutics employs 142 staff and has a trailing 12-month revenue of around USD$25 million.

How to buy shares in Turning Point Therapeutics

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Turning Point Therapeutics. Find the stock by name or ticker symbol: TPTX. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Turning Point Therapeutics reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. Weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Turning Point Therapeutics, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Turning Point Therapeutics. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Turning Point Therapeutics share price

Use our graph to track the performance of TPTX stocks over time.

Turning Point Therapeutics shares at a glance

Information last updated 2021-04-09.
52-week rangeUSD$46.75 - USD$141.3
50-day moving average USD$105.3659
200-day moving average USD$111.6503
Wall St. target priceUSD$160.1
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-5.251

Buy Turning Point Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
A free way to invest in stocks, ETFs and crypto.
Stocks, Options, ETFs, Gold/Commodities
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Interactive Brokers
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract, $1 minimum
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Stocks, Options, ETFs
Get one free stock valued between $2.50 and $250 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Stocks, ETFs
$0 per month

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Turning Point Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Turning Point Therapeutics financials

Revenue TTM USD$25 million
Gross profit TTM USD$25 million
Return on assets TTM -10.36%
Return on equity TTM -20.78%
Profit margin 0%
Book value $22.801
Market capitalisation USD$4 billion

TTM: trailing 12 months

Shorting Turning Point Therapeutics shares

There are currently 2.3 million Turning Point Therapeutics shares held short by investors – that's known as Turning Point Therapeutics's "short interest". This figure is 8.2% up from 2.1 million last month.

There are a few different ways that this level of interest in shorting Turning Point Therapeutics shares can be evaluated.

Turning Point Therapeutics's "short interest ratio" (SIR)

Turning Point Therapeutics's "short interest ratio" (SIR) is the quantity of Turning Point Therapeutics shares currently shorted divided by the average quantity of Turning Point Therapeutics shares traded daily (recently around 313116.71232877). Turning Point Therapeutics's SIR currently stands at 7.3. In other words for every 100,000 Turning Point Therapeutics shares traded daily on the market, roughly 7300 shares are currently held short.

However Turning Point Therapeutics's short interest can also be evaluated against the total number of Turning Point Therapeutics shares, or, against the total number of tradable Turning Point Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Turning Point Therapeutics's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Turning Point Therapeutics shares in existence, roughly 50 shares are currently held short) or 0.0624% of the tradable shares (for every 100,000 tradable Turning Point Therapeutics shares, roughly 62 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Turning Point Therapeutics.

Find out more about how you can short Turning Point Therapeutics stock.

Turning Point Therapeutics share dividends

We're not expecting Turning Point Therapeutics to pay a dividend over the next 12 months.

Turning Point Therapeutics overview

Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+, NTRK+, or ALK+ advanced solid tumors. Its pipeline also includes multi-targeted drug candidates TPX-0022, a MET/CSF1R/SRC inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in Phase 1/2 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, a preclinical ALK inhibitor for advanced non-small-cell lung cancer. The company was founded in 2013 and is headquartered in San Diego, California.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site